BONO USA

Bono Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule drugs for cancer treatment. The company specializes in targeting historically undruggable proteins within the RAS signaling pathway, which is a major driver in various solid tumors. Headquartered in Shanghai with a significant research and development presence in Princeton, New Jersey (operating as Bono USA), the company leverages its proprietary drug discovery platform to advance a pipeline of precision oncology candidates. Their lead program, BT-001, is a potent and selective KRAS G12C inhibitor currently in Phase 1 clinical trials. Bono Therapeutics aims to provide effective therapeutic options for patients with advanced cancers who have limited treatment alternatives.